However, it is not known if ERα+/ERβ+ expressing breast cancer would benefit using a treatment strategy combining tamoxifen and fulvestrant or if fulvestrant exert any therapeutic effects in ERα-/ERβ+ breast cancer. Here, ESR2 is linked to breast cancer.